Progress on S.B. 790 in California to Exempt Blinded Pharmaceutical Marketing Research - Articles

Articles

Stay at the forefront of the consumer insights and analytics industry with our Thought Leadership content. Here you’ll find timely updates on the Insights Association’s advocacy efforts, including the latest legislative and regulatory developments that impact how we work. In addition, this section offers expert perspectives on innovative research techniques and methodologies, as well as valuable analysis of evolving consumer trends. Together, these insights provide a trusted resource for professionals looking to navigate change, elevate their practice, and shape the future of our industry.

Progress on S.B. 790 in California to Exempt Blinded Pharmaceutical Marketing Research

Progress on S.B. 790 in California to Exempt Blinded Pharmaceutical Marketing Research

The sponsor of S.B. 790, a bill that would otherwise ban respondent incentives for California doctors participating in most pharmaceutical marketing research, has agreed to the Insights Association's amendment that would exempt bona fide research from the ban.

Sen. Mike McGuire has agreed to accept our amendment proposal, as you can see in the latest circulated draft on page 5, and the latest published version of the bill.

However, the fate of this bill is uncertain. According to our Sacramento lobbying firm, several specialty physician groups, hospital groups, and pharmaceutical companies are battling over their own amendment proposals and newly oppose the bill until their concerns are satisfied. After considering a delay, the Assembly Health Committee will go ahead with a planned hearing on June 27 while Sen. McGuire and committee staff continue to revise the bill text. Consequently, the bill's language is in flux and we are taking nothing for granted.

Your assistance is still needed. As many members have already done, we urge you (or your colleagues, partners, vendors and friends) in California to contact your specific California Assembly members to support S.B. 790 with the Insights Association's amendment exempting blinded marketing research with doctors. If possible, you should share a compelling story about the value of pharmaceutical marketing research with medical professionals, like Carlos Garcia's story.

Related

Share

Login

Members only Article - Please login to view
  • Back to top